UnicoCell Biomed Co., Ltd. is a biomedical company that mainly focuses on the development of stem cell therapeutic product, cell therapy technology, and regenerative medicine applications. It offers ELIXCYTE is an allogeneic adipose stem cell product for the treatment of knee osteoarthritis and chronic kidney disease and CT31-ELIXCYTE is a product for treatment of renal failure. The company was founded on March 28, 2018 and is headquartered in Taipei, Taiwan.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company